Orange County
Nigerian faces 10 years in jail for obtaining U.S. citizenship using fake identity
The United States authorities have charged 48-year old Modestus Nwagubwu Ifemembi to court over fraudulent claims he provided to obtain the US citizenship 10 years back. Ifemembi, who secured his US citizenship in 2001, has worked as a Federal providers’ officer with the U.S. Citizenship and Immigration Services (USCIS) for seven years. According to a report by the US Department of Justice (DOJ), Ifemembi, originally of Nigeria, was arrested in Maryland on Wednesday, April 7, 2020, on a federal charge that he obtained U.S. citizenship under a false name. It added that he made false statements to acquire U.S. citizenship, in addition to employment with USCIS. The report disclosed that Ifemembi was charged under the false name of Karl Nwabugwu Odike Ifemembi. His arrest followed investigatio...
Gold rises on renewed US stimulus hope, dollar falls
Spot gold rose 0.3 percent to $1,910.56 an ounce at 3:37pm, New York time, after falling as much as 0.5 percent. Gold rose on renewed optimism for a preelection aid package in the U.S., while the dollar fell to a one-week low. House Speaker Nancy Pelosi said a bill for a compromise stimulus package is being written as she awaits a key phone call with Treasury Secretary Steven Mnuchin. Senate Majority Leader Mitch McConnell said his chamber would take up a comprehensive coronavirus package if an accord is struck. The Bloomberg Dollar Spot Index headed for the third straight decline. Pelosi said in a Bloomberg Television interview that while there are areas where more work is required to get a compromise, she was pleased with the Trump administration’s latest position on coronavirus testing ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
